BofA analyst Jason Gerberry lowered the firm’s price target on Vaxcyte (PCVX) to $133 from $134 and keeps a Buy rating on the shares. The firm, which sees “no surprises” from the Q4 business update, remains bullish on the stock setup into Phase 3 adult data for VAX-31, calling it “a key catalyst that can derisk” a 2027 BLA filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCVX: